NCT02659059
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT02659059
Title Nivolumab Plus Ipilimumab to Treat First Line Stage IV Non-Small Cell Lung Cancer (CheckMate568)
Acronym CheckMate 568
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors Bristol-Myers Squibb
Indications
Therapies
Age Groups: adult
Covered Countries USA | CAN

*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field